©1995 by The American Society for Biochemistry and Molecular Biology, Inc.
In Vivo Assembly of the Proteasomal Complexes, Implications for Antigen Processing (*)

(Received for publication, June 30, 1995)

Young Yang (§) Klaus Früh Kwangseog Ahn Per A. Peterson

From the R. W. Johnson Pharmaceutical Research Institute at The Scripps Research Institute, Department of Immunology, La Jolla, California 92037

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

The multicatalytic and multisubunit proteasomal complexes have been implicated in the processing of antigens to peptides presented by class I major histocompatibility complex molecules. Two structural complexes of this proteinase, 20 S and 26 S proteasomes, have been isolated from cells. By analyzing in vivo assembly of the proteasomal complexes we show that the 20 S proteasomal complexes are irreversibly assembled via 15 S assembly intermediates containing unprocessed beta-type subunits. The 20 S proteasomes further associate reversibly with proteasome activators PA28 or pre-existing ATPase complexes to form 26 S proteasomal complexes. Our findings that not all of the 20 S proteasomal complexes are assembled into 26 S proteasomal complexes within cells and that all of PA28 and ATPase complexes are associated with 20 S proteasomes strongly suggest that all proteasomal complexes coexist within cells. We further demonstrate that 26 S proteasomal complexes are predominantly present in the cytoplasm and a significant portion of the 20 S proteasomal complexes is associated with the endoplasmic reticulum membrane. Taken together, our findings suggest that depending upon their associated regulatory components, 26 S and 20 S-PA28 proteasomal complexes serve different housekeeping functions within the cells, while they degrade antigens in a cooperative manner in antigen processing.


INTRODUCTION

Cytotoxic T-lymphocytes recognize antigenic peptides of 8-10 amino acid residues presented by class I major histocompatibility complex (MHC) (^1)molecules(1) . This trimeric complex of class I MHC molecule is assembled in the endoplasmic reticulum from class I heavy chain, beta(2)-microglobulin, and antigenic peptide imported from the cytoplasm through a peptide transporter(2, 3, 4) . Because antigen exogenously introduced into the cytoplasm needs to be ubiquitinated before T-cell epitopes are generated(5) , it seems that antigenic peptide generation follows a ubiquitin-mediated protein degradation pathway. It has been shown that ubiquitinated proteins are degraded by the 26 S multicatalytic and multisubunit proteinase complex, or 26 S proteasome (6) and that inhibitors of the proteasomal complexes block the generation of peptides presented on class I MHC molecules(7) .

The 26 S proteasome consists of an ``ATPase complex'' (8) (or ``19 S complex''(9) ) and the 20 S proteasome which is believed to be the catalytic core of the 26 S proteasome(10, 11, 12) . The 20 S proteasome is a highly conserved structure of 7-fold symmetry in all eucaryotic cells and the archaebacterium Thermoplasma acidophilum(10, 11, 12) . The x-ray crystallographic analysis of the 20 S proteasome from the archaebacterium T. acidophilum has recently been reported(13) . The 20 S proteasome of eucaryotes consists of a family of 14 different subunits of molecular masses between 20 and 35 kDa(14, 15) . The subunits can be classified into seven different but homologous alpha-type or beta-type subunits according to their homology with the alpha- and beta-type subunits of the T. acidophilum proteasome(16, 17) . In addition, three additional beta-type subunits, LMP2, LMP7, and MECL1, are up-regulated by interferon (IFN)(15, 18, 19, 20, 21, 22, 23, 24) . The MHC-encoded and IFN-inducible LMP2 and LMP7 (23) are found to displace two constitutively expressed and highly homologous housekeeping beta-type subunits 2 and 10, respectively, from the proteasomal complexes(23, 24) , thus changing the subunit composition without altering the number of subunits per complex. Although incorporation of LMP2 and LMP7 is not an essential prerequisite for peptide generation(25, 26) , the enzymatic activities of proteasomal complexes are thereby altered in such a way that preferred peptidic substrates for peptide transporters and class I molecules are generated (27, 28, 29, 30, 31) . (^2)Further circumstantial evidence for the involvement of proteasomal complexes in antigen processing came from studies of a family of homologous proteasome activators PA28 (32, 33, 34, 35) which consists of at least two IFN-inducible homologues.^2 It has been shown that in vitro binding of PA28 to 20 S proteasomes activates distinct peptidase activities of 20 S proteasomes (32, 33, 34) ,^2 indicating that peptide products appropriate for antigen presentation may be preferentially generated.

Both 20 S and 26 S proteasomes can be isolated from cells(11, 12, 14, 18) , but it has not been clearly established whether both complexes coexist in vivo. We have therefore studied the individual steps leading to the formation of 26 S proteasomal complexes. We show that beta-type subunit precursors assemble into distinct assembly intermediates prior to processing, whereby the amino-terminal sequences play a crucial role. The assembly of 20 S proteasomes is completed with the association of additional subunits to the assembly intermediate during and/or after beta-type subunits are processed, whereas the assembly of 26 S proteasomal complexes occurs in a single step from the pre-existing ATPase complexes and 20 S proteasomes. Furthermore, we present the first in vivo observation that IFN-inducible proteasome activators PA28 directly bind to 20 S proteasomes and that binding of PA28 does not interfere with the assembly of 26 S proteasomal complexes. Although the assembly of 20 S proteasomes is irreversible, assembly of the 26 S proteasomal complexes, possibly mediated by subunit phosphorylation, is reversible. Our demonstration that 20 S and 26 S proteasomal complexes localize in different subcellular compartments further suggests the differential functions of 20 S and 26 S proteasomal complexes in antigen processing.


MATERIALS AND METHODS

Cell Cultures and Antisera

The murine lymphoma RMA cells (3) were grown in RPMI 1640 medium. For transactivator-containing HtTa cells(24, 36) , 500 µg/ml G418 and 0.1 µg/ml tetracycline (Sigma) were included into Dulbecco's modified Eagle's medium (BioWhittaker) supplemented with 10% fetal calf serum. For IFN induction, cells were treated with 500 units/ml of recombinant mouse IFN (Boehringer Mannheim) for 48 h. The anti-C9, anti-LMP2, and anti-proteasome antisera were raised in rabbits against recombinant murine C9, murine LMP2, and purified bovine 20 S proteasome as described(22, 24) . The anti-PA28 antiserum was raised against a synthetic peptide corresponding to the carboxyl-terminal 20 amino acid residues of human PA28(34) . A rabbit antiserum to ATPase complexes was kindly provided by M. Rechsteiner.

DNA Constructs and Transfection

The cDNAs coding for hLMP7-E1, hLMP7-E2, hLMP2, and mLMP2 were subcloned from pCMUII (22) into pUHD10-1(36) . mLMP7 was subcloned from pUHG10-3(24) . In the process of this cloning a consensus eucaryotic translation initiation sequence was introduced in front of all start codons. The cDNA coding for PA28 was isolated from a cDNA library of HeLa cells by polymerase chain reaction using specific primers (34) and was cloned into pUHG10-3. The LMP or PA28 cDNA constructs were transfected together with a plasmid confering resistance against ouabain into HtTa cells by the calcium phosphate method. After 16 h, cells were washed in phosphate-buffered saline and incubated in Dulbecco's modified Eagle's medium, 10% fetal calf serum for an additional 24 h. Ouabain (Sigma) was then added to a final concentration of 1 µM. Untransfected cells died within the next 24 h. The surviving cells were labeled for immunoprecipitation as described below. For studies on PA28, from several stable clones a single stable transfectant was selected for further investigation.

Metabolic Radiolabeling and Immunoprecipitation

Metabolic labeling of cells was carried out as described (23) with the following modifications. Pulse labeling media contained 0.3 mCi of TranS-label mixture (ICN) per ml of methionine-deficient RPMI or Dulbecco's modified Eagle's medium. Cells were labeled for 0.5, 1, or 4 h followed by chase periods of different lengths of time in the presence of normal culture medium. Immunoprecipitation, SDS-polyacrylamide gel electrophoresis, first-dimension nonequilibrium pH gradient gel electrophoresis (using Ampholines pH 3.5-10), and fluorography were carried out as described (23) .

Sucrose Gradient Fractionation

RMA or stable PA28-expressing HtTa transfectant cells were homogenized in the isotonic sucrose solution described in (23) . For isolation of 20 S complexes, ATP in homogenates was depleted by including 100 units/ml hexokinase and 10 mM glucose in the isotonic solution. For isolation of the 26 S complexes, the isotonic sucrose solution was supplemented with 5 mM MgCl(2) and 2 mM ATP and the resultant homogenates were layered on top of a 10-40% linear sucrose gradient containing 25 mM Hepes, 1 mM EDTA, 5 mM MgCl(2), 2 mM ATP, pH 7.5. The gradient volume was 12 ml. Samples were centrifuged for 4 h at 25,000 rpm using a Beckman SW 27 rotor and 0.5 (Fig. 2) or 0.6 ml (Fig. 4Fig. 5Fig. 6) per fraction was collected and used for immunoprecipitation.


Figure 2: Assembly of 20 S proteasomal complexes. Proteasomes were immunoprecipitated from sucrose gradient fractions of homogenates prepared from RMA cells after labeling for 30 min (A) and chasing for 2 h (B). The antiserum used was raised against recombinant subunit C9 and precipitates both free (fractions 1-2) and complexed (fractions 3-12) subunit C9(22) . The positions of the MHC-encoded subunits LMP2 and LMP7 as well as their precursors are marked. Sedimentation coefficients for fractions 5 and 9 were approximately 15 S and 20 S, respectively.




Figure 4: Assembly of 26 S proteasomal complexes. RMA cells were labeled for 30 min (A) followed by 2 h chase (B), 6 h chase (C), or 12 h chase (D). Fractionation of RMA cell homogenates was performed as in the legend to Fig. 2, except that 2 mM ATP and 5 mM MgCl(2) were included in cell homogenization isotonic solution and sucrose gradients. Subunits smaller than 32 kDa belong to the 20 S proteasomes (see Fig. 2), subunits larger than this molecular mass are part of the ATPase complexes (see Fig. 5). The sedimentation coefficient for the complexes at fraction 11 was approximately 26 S. Some of the proteasomal subunits as well as their precursors are indicated. The ^14C-methylated protein markers (M) are myosin (200 kDa), phosphorylase b (97.4 kDa), bovine serum albumin (69 kDa), ovalbumin (46 kDa), carbonic anhydrase (30 kDa), and lysozyme (14.3 kDa). E, the enzymatic activities of the different proteasomal complexes present in each sucrose gradient fractions were assayed for hydrolysis of the fluorogenic peptidic substrate succinyl-LLVY-AMC.




Figure 5: ATPase complexes associate rapidly with pre-existing 20 S proteasomes. RMA cell homogenates were fractionated as described in the legend to Fig. 4except that RMA cells were labeled for 1 h (A and C) followed by a 4-h chase (B and D) prior to fractionation and immunoprecipitation with anti-ATPase complex antiserum (A and B) or anti-C9 antiserum (C and D). Only fractions 5-14 are shown. Sedimentation coefficients for fractions 5, 8, and 11 were approximately 15 S, 20 S, and 26 S, respectively. Note that the ATPase complexes associate with unlabeled 20 S proteasomes under these labeling conditions (compare A and C). A similar pattern to C was also observed for Fig. 4A upon longer exposure of the fluorogram. Proteins immunoprecipitated by the anti-ATPase complex antiserum in fractions other than 9-12 are most likely nonspecific, since they remained unchanged during the chase period (compare A and B).




Figure 6: Proteasome activators PA28 bind to 20 S proteasomes. The expression of IFN-inducible PA28 in the stable PA28-expressing HtTa transfectant cells was induced by the removal of tetracycline for 16 h prior to [S]methionine labeling for 30 min followed by a 4-h chase. Fractionation of cell homogenates was performed as described in the legend to Fig. 4. Each fraction was equally divided into two aliquots and immunoprecipitated either with anti-proteasome (left panel) or anti-PA28 antisera (right panel).



Cellular Fractionation

RMA cells were labeled for 30 min followed by a chase of 4 h and homogenized as described(23) . The homogenates were first spun for 30 min at 13,000 rpm to collect the nuclei. Cytosolic and crude microsomal fractions were separated by spinning at 100,000 times g for 30 min. Proteasomal complexes were immunoprecipitated from each fraction and analyzed by SDS-gel electrophoresis.

In Vivo Phosphorylation

RMA cells were labeled in phosphate-free Dulbecco's modified Eagle's medium supplemented with dialyzed serum containing [P]orthophosphate (Amersham) (0.5 mCi/ml) for 4 h. After adding 1 µM okadaic acid and 0.1 µM calyculin A (Calbiochem) cells were cultured for an additional 30 min prior to lysis in 1% Nonidet P-40 lysis buffer containing phosphatase inhibitors (1 µM okadaic acid, 0.1 µM calyculin A, 50 mM NaF, 30 mM pyrophosphate, and 0.1 mM Na(3)VO(4)) followed by immunoprecipitation.


RESULTS

Precursor Processing Is a Requirement for Incorporation of beta-Type Subunits

The human LMP7-gene codes for two alternatively spliced mRNAs, LMP7-E1 and LMP7-E2, which differ only in their amino-terminal prosequence(22) . However, only LMP7-E2 is expressed as a protein in vivo(22) , which might reflect the lack of appropriate translation signals upstream from the start codon in LMP7-E1. We therefore examined whether LMP7-E1, expressed as a LMP7 precursor protein, can be incorporated into proteasomal complexes by transient transfection of HeLa cells with LMP7-E1 cDNA (Fig. 1). We had previously reported that in LMP7-E1-transfected HeLa cells the incorporation of LMP7 into proteasomal complexes was slightly increased(22) . However, these initial experiments were difficult to interpret due to low expression levels and low transfection efficiencies of LMP7 as well as the fact that HeLa cells express relatively high levels of endogenous LMP7. By increasing expression levels and transfection efficiencies as described under ``Materials and Methods'' and by using a subclone of HeLa cells, HtTA, which expresses almost no endogenous LMP7(24) , we observed that the precursor proteins of all transfected-LMP7 constructs were expressed at high levels (lanes 1, 3, and 5 of Fig. 1) comparable to the expression level of endogenous LMP7 induced by IFN (lane 8).


Figure 1: Incorporation of beta-type subunit LMP7 into proteasomal complexes. HtTA cells were either transfected with murine LMP7 (lanes 1 and 2), human LMP7-E2 (lanes 3 and 4), human LMP7-E1 (lanes 5 and 6), or un-transfected but induced (lanes 8 and 9) or uninduced (lane 7) with IFN. After [S]methionine metabolic labeling, cells were lysed and proteins were immunoprecipitated with either anti-LMP7 antiserum (22) (lanes 1, 3, 5, and 8) or anti-proteasome antiserum (24) (lanes 2, 4, 6, 7, and 9). The positions of precursors and processed products of human and mouse LMP7 are indicated.



When we immunoprecipitated the proteasomal complexes, protein bands corresponding to the processed forms of LMP7 were present only in proteasomal complexes from cells transfected with either human LMP7-E2 (Fig. 1, lane 4) or mouse LMP7 (lane 2) but not human LMP7-E1 (lane 6). No processed LMP7-E1, which should be identical to processed transfected- or IFN-induced endogenous LMP7-E2, was detected in overexposed fluorograms either (not shown); thus, it seems that only LMP7-E2 gives rise to a functional protein. We conclude that the amino-terminal prosequence is crucially involved in the mechanism by which beta-type subunits are assembled into the proteasomes. Our finding in conjunction with the observations that the prosequences differ significantly among different beta-type subunits and that the sequences surrounding the cleavage site (17, 24) are highly conserved suggest that the prosequences might play a subunit-specific role in the initial folding and/or assembly of beta-type subunits (see below), whereas the cleavage is performed by a specific protease.

20 S Proteasomes Assemble via 15 S Assembly Intermediates Containing beta-Type Subunit Precursors

To examine whether precursor processing of the beta-type subunit occurs before or after the assembly of proteasomal complexes, we combined pulse-chase labeling with sucrose gradient fractionation of homogenates prepared from RMA cells constitutively expressing both LMP2 and LMP7. Proteasomal complexes contained in such fractions were immunoprecipitated using an antiserum specific for the alpha-type subunit C9 (22) and an antiserum to the proteasome (not shown). As shown in Fig. 2A, immediately after labeling, anti-C9 antiserum immunoprecipitated both free non-assembled subunit C9 (fractions 1-3) and two additional distinct complexes, one with a 15 S sedimentation coefficient (fractions 4-7) and the other with a 20 S sedimentation coefficient (fractions 8-11). After a 2-h chase, both the free C9 subunit and the 15 S complexes were no longer detectable and all the label was chased to the 20 S complexes in fractions 8-11 (Fig. 2B). A similar finding was also obtained by using an anti-proteasome antiserum in the same experiments (not shown). We conclude that the 15 S complexes are the assembly intermediates of the 20 S complexes. Interestingly, when an anti-LMP2 antiserum (22) was used in the same experiments, only the free LMP precursor protein and 15 S complexes were detected in pulse-labeled samples (not shown). The observation that even after longer chase periods (2-18 h) no 15 S and 20 S complexes were detected suggests that after completion of the 20 S complex assembly, LMP2 is no longer recognized by the anti-LMP2 antiserum. Since the antiserum was raised against recombinant LMP2 protein, the inaccessibility of anti-LMP2 antibodies to LMP2 epitopes is likely due to the addition of other subunits to the 15 S complexes, or conformational change of the LMP2 subunit occurring within the 20 S complexes.

In order to determine whether there are differences among these complexes, we compared the subunit composition of the ``anti-LMP2 15 S complexes'' with the ``anti-C9 15 S complexes'' as well as with the 20 S complexes by two-dimensional gel electrophoresis. As shown in Fig. 3, the subunit compositions of 15 S complexes immunoprecipitated by anti-C9 or LMP2 antisera were almost identical but differed in a number of subunits from the 20 S complex and the 20 S complexes displayed the typical two-dimensional pattern of 20 S proteasomes(23) . Furthermore, subunits common to all three complexes were identified as alpha-type subunits by using a panel of subunit-specific antisera and two-dimensional immunoblots as described (22) . Interestingly, alpha-type subunit C3 displayed a charge shift in the anti-LMP2 15 S complexes indicating post-translational modifications. Among the subunits differing between 15 S and 20 S complexes, four subunits in the 15 S complexes could be identified as precursors of the beta-type subunits, pC5, pLMP2, pLMP7, and an unidentified beta-type subunit p, whereas their processed forms are only present in the 20 S proteasomes (Fig. 3B). Since beta-type subunit precursors are only present in the 15 S assembly intermediates, we conclude that beta-type subunits assemble into 15 S complexes prior to their processing.


Figure 3: Subunit compositions of 15 S assembly intermediates and 20 S proteasomal complexes. The same sucrose gradient fractions 5 (C and D) and 9 (B) from Fig. 2were immunoprecipitated with either anti-C9 (B and D) or anti-LMP2 (C) antisera (22) and immunoprecipitates were resolved according to charge and molecular mass(23) . A, schematic summary of the subunit composition common to (black) or different between (open and dotted) the 20 S proteasomal complexes (B) and the 15 S assembly intermediates (D). Compared to the subunit composition of the anti-C9 15S complexes (D), two subunits indicated with arrows are absent from the anti-LMP2 15 S complexes (C). Subunits or their precursors (``p'') identified in two-dimensional immunoblots with a panel of subunit-specific antisera (22) are indicated. It is conceivable that the seven subunits (black) common to the 20 S and 15 S complexes are alpha-type subunits and that beta-type subunit precursors are allowed to associate with the 7-fold structural backbone composed of alpha-type subunit, thus forming 15 S complexes.



The almost identical subunit composition and half-life of both the 15 S assembly intermediates recognized by anti-C9 and anti-LMP2 antisera as well as similar complexes observed by Frentzel et al.(37) and Patel et al.(38) indicates a time-limited step at this point of proteasomal complex assembly. Our data further show that 20 S proteasome assembly is an irreversible process, because free processed beta-type subunits could not be detected within the cells(24) . In addition, our findings that no beta-type subunit precursors were detected in 20 S complexes and no intermediate assembly complexes of alphabeta rings (see below) were detected suggest that the completion of 20 S proteasomal complex assembly, i.e. prosequence cleavage and dimerization of the two alphabeta rings, occurs rather rapidly. We conclude that due to this irreversible process, homologous subunit exchanges can only take place during assembly of the 15 S complexes, as we have indeed observed for LMP subunits(24) . Interestingly, although both LMP2 and subunit 2 are present in 20 S proteasomes of RMA cells, indicating a mixed proteasome population, only the LMP2 precursor is detected in the 15 S assembly intermediates immunoprecipitated by either anti-C9 or anti-LMP2 antisera. This suggests that the order of assembly with other subunits is different for LMP2 than for subunit 2.

The 26 S Proteasomes Are Formed by Assembly of the Pre-existing ATPase Complexes and 20 S Proteasomes

To address the question whether the 26 S proteasomes assemble via 20 S proteasomes or via individual proteasome subunit associates with ATPase complexes, the assembly of the 26 S complexes were monitored as in Fig. 2, except that MgCl(2) and ATP were present at all stages of sample preparation from cell homogenization, fractionation, and immunoprecipitation in order to stabilize the 26 S complexes(12, 18) . As shown in Fig. 4A, under these conditions the initial assembly steps of 26 S complexes were identical to the assembly of the 20 S proteasomes described above. However, during prolonged chase (Fig. 4, B-D) additional proteins of higher molecular mass between 35 and 250 kDa were associated with the 20 S proteasomes resulting in complexes with a 26 S sedimentation coefficient at fraction 11. The protein pattern of these high molecular mass subunits resembled closely the pattern of the ATPase complexes as described by Hoffman and Rechsteiner(8) . This was indeed confirmed, when 26 S complex formation was studied with an antiserum specific for the ATPase complex. As shown in Fig. 5, A and C, immediately after pulse labeling the ATPase complexes were detected in fractions 9-12, whereas the labeled 26 S complexes were only detectable after chase (Fig. 5, B and D). It is unlikely that free ATPase complexes and 26 S proteasomal complexes comigrate in the same sucrose gradient fractions, since isolated ATPase complexes have a 19 S sedimentation coefficient (8, 11, 12) . The finding that the ATPase complexes were only detectable in the same sucrose gradient fractions 9-12 as the 26 S complexes strongly suggests that the newly synthesized and assembled ATPase complexes have associated with un-labeled 20 S proteasomes. Since all non-20 S proteasome subunits appeared simultaneously in the anti-C9 immunoprecipitate and, vice versa, all 20 S proteasome subunits appeared together in the anti-ATPase complex immunoprecipitate, we conclude that the 26 S complexes are formed by association of the two preformed complexes. No evidence was obtained in favor of an assembly pathway whereby subunits of either the 20 S or ATPase complex associate individually to the other complex.

Because the anti-ATPase complex polyclonal antiserum is raised against isolated ATPase complexes, it is unlikely that this antiserum does not recognize free ATPase complexes. Our data indicating that no preformed free ATPase complexes were detected in other fractions (not shown) also suggests that the amount of the ATPase complexes is limiting in cells and that these complexes associate rapidly with the pre-existing 20 S proteasomal complexes. These findings in conjunction with the observation that only about 40% of the label present in the 20 S complexes is converted to the 26 S complexes even after prolonged chase (Fig. 4D) further suggests that the free 20 S proteasomal complexes coexist with 26 S proteasomal complexes within the cells and are not the dissociation products of 26 S complexes. We next studied the enzymatic activities of the different proteasomal complexes present in sucrose gradient fractions for hydrolysis of the succinyl-LLVY-AMC, a fluorogenic peptidic substrate commonly used for detection of proteasome activity(11, 12) . The enzymatic activities were only detected in fractions containing the 20 S and 26 S complexes, whereas no enzymatic activity was observed for the fractions containing free subunits or 15 S assembly intermediates (Fig. 4E). This result indicates that only after cleavage of the beta-type subunit prosequences are proteasomal complexes enzymatically active.

Proteasome Activators PA28 Bind to 20 S Proteasomes in Vivo

Contrary to previous findings that purified 20 S proteasomes are rather enzymatically inactive regardless whether their housekeeping subunits are displaced by MHC-encoded LMPs or not (11) , (^3)our data that fractions containing 20 S or 26 S proteasomes have higher enzymatic activities (Fig. 4E) suggest that additional components are required for purified 20 S proteasomes to be enzymatically active. Support for this view came from in vitro studies on PA28(18, 32, 33, 34, 35) . It has been shown that purified PA28 is associated with purified 20S proteasomes in vitro(32, 33, 34) and that PA28 stimulates purified 20 S proteasomes to cleave after hydrophobic or positive charge residues at the carboxyl terminus of fluorogenic peptidic substrates(32, 33, 34) . We, therefore, examined whether in vivo binding of IFN-inducible PA28 to 20 S proteasomes occurs and whether the ATPase complex is displaced from 26 S proteasomes by PA28 in vivo. Homogenates prepared from stable PA28-expressing HtTa transfectant cells were fractionated in 10-40% sucrose gradients and the resulting fractions were analyzed by immunoprecipitations for the presence of PA28 and 20 S as well as 26 S proteasomes using antisera specific to proteasomes or PA28. As shown in Fig. 6, 20 S and 26 S proteasomes were detected at fractions 8-9 and 10-12, respectively, whereas PA28 was mainly present at 20 S proteasome-containing fraction 9, indicating that PA28 binds to 20 S proteasomes. Since the intensities of 20 S and 26 S proteasomes at respective fractions were not changed regardless of the expression of PA28 (data not shown), PA28 appears to be associated with free 20 S proteasomes. This is the first demonstration that PA28 and 20 S proteasomes associate in vivo.

Subcellular Localization of 15 S Assembly Intermediates, 20 S and 26 S Proteasomes

The observation that distinct proteasomal complexes coexist within the cell raised the question whether they would be distributed within different subcellular compartments. We therefore analyzed the intracellular distributions of the 15 S, 20 S, and 26 S complexes by subcellular fractionation of pulse-chase-labeled RMA cell homogenates followed by immunoprecipitation with anti-C9 or anti-LMP2 antisera. As shown in Fig. 7, 20 S proteasomes were equally distributed among the nuclear, cytosolic, and microsomal fractions. By contrast, 26 S proteasomal complexes were predominantly present in the cytosolic fraction, very little in the nuclear fraction, and were completely absent from the microsomal fraction (compare to Fig. 4B for the presence of ATPase complexes). Similarly, the majority of the 15 S assembly intermediates were only detected from the cytosol by both antisera but were absent from nuclear and microsomal fractions. These findings suggest that the 15 S and 20 S complexes assemble in the cytoplasm, where 20 S complexes further associate with the ATPase complexes to form the 26 S complexes. Consistent with the immunocytochemical and immunoelectron microscopic studies that up to 14% of proteasomes are close or actually on the endoplasmic reticulum(11) , we found that a significant proportion of 20 S proteasomeal complexes not only remain in free forms but also have different cellular localizations than the 26 S proteasomal complexes.


Figure 7: Distinct subcellular distribution of 20 S and 26 S proteasomal complexes. Cell homogenates prepared from RMA cells labeled for 0.5 h (odd-numbered lanes) followed by a 2-h chase (even-numbered lanes) were fractionated into three subcellular fractions by differential centrifugation: nuclei (lanes 1 and 2), cytosol (lanes 3 and 4), and microsomes (lanes 5 and 6). Immunoprecipitations were performed by using anti-C9 (left panel) or anti-LMP2 (right panel) antisera.



Regulation of Proteasomal Complex Assembly

A comparison of the subunit compositions of the two assembly intermediates and the mature 20 S complexes shown in Fig. 3suggested that some of the different subunits were in fact different modifications of the same subunit. For instance, the charge of subunit C3 (lower left) was different between the ``anti-LMP2 intermediate'' and the ``anti-C9 intermediate.'' Likewise subunit 17 (upper right; (23) ) appeared as a streak. A possible explanation for these observations is post-translational modification due to phosphorylation(40, 41, 42) . Indeed, we found that two subunits of the 20 S complex and two subunits of the ATPase complex were predominantly phosphorylated as shown by in vivoP labeling followed by immunoprecipitation (Fig. 8A). According to their electrophoretic mobility the two phosphorylated ATPase complex subunits correspond to subunits S6 and S10 (43) and the two phosphorylated 20 S subunits correspond to subunits 17 and 18(23) . The extent of in vivo phosphorylation of both ATPase complex subunits was diminished in the presence of okadaic acid and calyculin A, inhibitors of serine/threonine phosphatases, whereas the extent of phosphorylation for subunit 18 of the 20 S complexes was not affected and was increased for subunit 17 in the presence of okadaic acid and calyculin A. Thus, different kinases and phosphatases seem to be responsible for phosphorylation of the ATPase complexes compared to the 20 S complexes.


Figure 8: Regulation of proteasomal complex assembly. A, some subunits of 20 S proteasomes and ATPase complex are phosphorylated. RMA cells were lysed in 1% Nonidet P-40 lysis buffer containing phosphatase inhibitors (1 µM okadaic acid, 0.1 µM calyculin A, 50 mM NaF, 30 mM pyrophosphate, and 0.1 mM Na(3)VO(4)) after labeling with either [P]orthophosphate (lanes 1 and 2) or [S]methionine (lane 3). 26 S complexes from cell lysates were immunoprecipitated using the anti-C9 antiserum. Predominantly phosphorylated subunits are indicated. In lane 2 cells had been incubated with 1 µM okadaic acid and 0.1 µM calyculin A during labeling. B, effect of okadaic acid/calyculin A on proteasomal complex assembly. RMA cells were untreated (lanes 1 and 2) or treated (lanes 3 and 4) with 1 µM okadaic acid and 0.1 µM calyculin A for 0.5 h prior to and during labeling (0.5 h). Proteasomes were either directly (lanes 1 and 3) or after 4-h chase (lanes 2 and 4) immunoprecipitated with anti-LMP2 antiserum. C, effect of cycloheximide on proteasomal complex assembly. RMA were induced (lanes 2 and 4) or uninduced (lanes 1 and 3) by IFN for 48 h prior to 30 min metabolic labeling. After labeling, cells were cultured for an additional 1 h in the absence (lanes 1 and 2) or presence (lanes 3 and 4) of 1 µM cycloheximide. Proteasomes were immunoprecipitated directly using the anti-C9 antiserum. D, staurosporine inhibits assembly of 26 S complexes. RMA cells were labeled for 4 h and the label was chased for 0 (lanes 1 and 7), 24 (lanes 2 and 8), 48 (lanes 3 and 9), 72 (lanes 4 and 10), 96 (lanes 5 and 11), and 120 h (lanes 6 and 12) either in the absence (left panel) or presence (right panel) of 0.5 µM staurosporine.



Since no phosphorylated subunits were detected in 15 S assembly intermediates by in vivoP labeling followed by immunoprecipitation with anti-LMP2 antiserum (data not shown), it is unlikely that phosphorylation plays a role in assembly of the 15 S assembly intermediates. We therefore studied whether phosphorylation and dephosphorylation would have an effect on the assembly of the 20 S and 26 S proteasomal complexes. RMA cells were either treated in vivo with the serine/threonine phosphatase inhibitors okadaic acid and calyculin A (Fig. 8B) or with the kinase inhibitor staurosporine (Fig. 8D). In addition, we analyzed the effect of cycloheximide (Fig. 8C) on the proteasomal complex assembly. As shown in Fig. 8C, the cycloheximide treatment resulted in drastically reduced assembly of the 20 S proteasome. Since under this condition the subunit composition of anti-C9 immunoprecipitates (only subunit 7 (23) coprecipitated significantly with the subunit C9) is simpler than 15 S assembly intermediates, we conclude that cycloheximide blocked assembly at a very early stage prior to 15 S complex formation, presumably due to the lack of newly synthesized subunits. By contrast, treatment by okadaic acid and calyculin A did not inhibit the assembly of the 15 S complexes but resulted in decreased processing of these assembly intermediates as shown by immunoprecipitating the 15 S complexes with anti-LMP2 antiserum (Fig. 8B). Similarly, a decreased rate of 20 S complex formation was also observed, when anti-C9 antiserum was used for immunoprecipitation (data not shown). Furthermore, when the kinase inhibitor staurosporine was used, the anti-C9 antiserum no longer coprecipitated the ATPase complexes with the 20 S complexes (Fig. 8D, right panel). We ruled out that this effect was due to an increased turnover of 26 S proteasomes, since after a prolonged chase period of several days no noticeable difference in the half-life of 20 S proteasomes between staurosporine-treated and untreated cells was observed (Fig. 8D). Consistent with the observation that in vitro the 26 S proteasome can be reversibly disassembled into the ATPase complex and 20 S complex by removal of ATP/Mg(11, 12) , we found that upon removal of staurosporine 26 S proteasomes were again detectable.^2 This effect of staurosporine indicates that kinases play a role in the assembly and disassembly of the 26 S complexes. Since staurosporine treatment gives a similar result in vivo, we propose that the role of ATP in 26 S complex assembly is dependent on an ATP-dependent protein kinase. It is interesting to note that PA28 is phosphorylated(42) , suggesting that phosphorylation may account for the association with the 20 S proteasomal complexes both for the ATPase complex and PA28.


DISCUSSION

Based on studies of the assembly and structure of Thermoplasma proteasomes (44, 13) and our findings presented in this paper, a hypothetical model for the in vivo assembly of 26 S complexes is proposed in Fig. 9. Eucaryotic beta-type subunits assemble on a ring-like structural backbone composed of seven alpha-type subunits. Thus, seven alpha-type subunits first associate among each other to form a ring-like structural backbone of seven-fold symmetry in which seven beta-type subunits are allowed to assemble. It is conceivable that each alpha-type subunit occupies a particular position within the ring-like structure and each beta-type subunit precursor also assembles in a given order by binding to the corresponding alpha-type subunits and each other. This process may lead to proteasomal complexes differing in the content of their exchangeable subunit homologues, e.g. LMP2 and LMP7. The beta-type subunit prosequences are immediately cleaved off either before or during the dimerization of the two alphabulletbeta-ring structural complexes. During assembly of proteasomal intermediate complexes, the prosequences of beta-type subunits might play a role in either the protein folding itself or the proteasome assembly process or by inactivating the enzymatic activity of the catalytic sites created during assembly. Thus, seven alpha-type and seven beta-type subunits each form a ring-like structure of 7-fold symmetry which further assembles into a dimer consisting of four-ring cylindrical structure in the order alphabetabetaalpha, i.e. the 20 S proteasomal complexes(11, 12, 13, 18) . The 20 S proteasomal complexes are then bound to regulatory components such as the ATPase complexes (16, 18) or the PA28(32, 33, 34, 35) . The 20 S proteasomal complexes are capped end-on by the ATPase complexes to form the 26 S complexes (16) or by the PA28(39) . Association with these regulatory components appears to be reversible. Once bound to the regulatory components the enzymatic activities of proteasomal complexes are activated.


Figure 9: Proposed assembly pathway of the proteasomal complexes. Seven alpha-type subunits first associate among each other to form a ring-like structural backbone of 7-fold symmetry in which seven beta-type subunits are allowed to assemble. Thus, seven alpha-type and seven beta-type subunits each form a ring-like structure of 7-fold symmetry which further assembles into a dimer consisting of a four-ring cylindrical structure in the order alphabetabetaalpha, i.e. the 20 S complexes. The 20 S proteasomal complexes are then capped end-on to regulatory components such as the PA28 or the ATPase complexes, thus forming the 26 S complexes. Association with these regulatory complexes appears to be reversible and probably regulated by phosphorylation.



The observations that upon induction of PA28 by IFN the molar ratios of PA28 and 20 S proteasomes, as well as ATPase complexes and 20 S proteasomes, are approximately 1:50 and 2:5, respectively,^2 supports the notion that there is a large pool of 20 S proteasomes within cells and that proteasome activities are modulated by regulatory components. It is conceivable that all 20 S proteasome-derived complexes serve specific purposes. The 26 S complexes seem to perform housekeeping functions, i.e. ubiquitin-dependent protein degradation, since the ATPase complexes are shown to be responsible for ubiquitin recognition and cleavage as well as regulatory functions(12) . The 20 S or 20 S-PA28 proteasomal complexes appear to cleave low-molecular mass peptidic substrates such as degradation intermediates, since 20 S or 20 S-PA28 complexes are rather inefficient in degrading whole proteins, even ubiquitinated proteins(12, 18, 32, 33, 34) . Since we found that all proteasome subunits, including the MHC-encoded LMP subunits, found in the 20 S proteasomal complexes were also found in the 26 S proteasomal complexes (Fig. 4) and that the ratios of LMP subunits to their exchanging homologous subunits remained the same between 20 S and 26 S complexes, we conclude that expressions of MHC-encoded LMP subunits affect both 20 S and 26 S proteasomal complexes. Therefore, our observations that subsets of 20 S complexes, differing with regard to their subunit composition, are also reflected in the subsets of 26 S complexes and that both 20 S-PA28 and 26 S complexes are enzymatically active suggest that both 20 S-PA28 and 26 S complexes may be involved in antigen processing. Our observations that peptide loading onto class I MHC molecules is interfered with by okadaic acid/calyculin A treatment(46) ,^2 which inhibits the in vivo assembly of 20 S proteasomal complexes, and that upon expression of PA28 the intracellular transport rate of class I MHC molecules increases 25%^2 in conjunction with our finding that IFN-inducible PA28 directly binds to 20 S proteasomes without interfering with the assembly of 26 S proteasomal complexes strongly suggest that 20 S-PA28 proteasomal complexes play a direct role in antigen processing. Moreover, our finding that at least two PA28 homologues are up-regulated by IFN^2 further supports the above hypothesis. It is interesting to note that isolated 20 S proteasomes of T. acidophilum have been shown to cleave small protein substrates into peptides with a length distribution centering around 8 amino acids(45) . Thus, it is reasonable to suggest that IFN-inducible LMP and PA28 serve to optimize antigen processing in proteasome-mediated protein degradation.

With regard to antigen processing for MHC class I antigen presentation, several parallel pathways could co-exist. 26 S proteasomal complexes could be responsible for antigenic peptide generation from ubiquitinated antigens, whereas 20 S or 20 S-PA28 proteasomal complexes could digest either partially unfolded antigens or newly synthesized abnormal polypeptides to antigenic peptides. This notion is consistent with the findings that 26 S proteasomal complexes but not 20 S or 20 S-PA28 proteasomal complexes are responsible for the degradation of ubiquitinated proteins and that distinct peptidase activities of 20 S proteasomes can be activated by IFN-inducible PA28. Alternatively, antigen degradation could occur in several successive steps conducted by various proteasomal complexes. 26 S proteasomal complexes could be the protease to degrade whole antigen into degradation intermediates and 20 S-PA28 complexes could function in further processing of such degradation intermediates into peptides of 8-10 amino acid residues suitable for class I loading. Based on our findings that 26 S proteasomal complexes are predominantly present in the cytoplasm and a significant portion of the 20 S proteasomal complexes is associated with endoplasmic reticulum membrane, it can be envisaged that after ubiquitinated proteins are fragmented by the 26 S proteasomal complexes, final trimming to the size of peptides required for transport and class I binding is perfomed by the 20 S-PA28 complexes in close spatial vicinity to the peptide transporters which are localized in the endoplasmic reticulum membrane. The direct association of 20 S proteasomal complexes and transporter-associated with antigen processing in the endoplasmic reticulum membrane could be an efficient means of transporting peptides generated by 20 S proteasomal complexes to transporter-associated with antigen processing. Our finding that no MHC class I peptide loading occurs^2 if the ubiquitination pathway is blocked (5) strongly supports the latter hypothesis.


FOOTNOTES

*
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
To whom correspondence should be addressed. Tel.: 619-554-4220; Fax: 619-554-6705.

(^1)
The abbreviations used are: MHC, major histocompatibility complex; IFN, interferon ; LMP, low molecular weight polypeptide.

(^2)
Y. Yang et al., unpublished data.

(^3)
Y. Yang et al., unpublished result.


ACKNOWLEDGEMENTS

We are indebted to Dr. M. Rechsteiner for anti-ATPase complex antiserum and Drs. H. Djaballah and P. Sempé for informative discussions and critical reading of the manuscript. The technical assistance of the protein and DNA facilities of the R. W. Johnson Pharmaceutical Research Institute is gratefully acknowledged.


REFERENCES

  1. Jackson, M. R. & Peterson, P. A. (1993) Annu. Rev. Cell Biol. 9, 207-235 [CrossRef]
  2. Momburg, F., Neefjes, J. J. & Hämmerling, G. J. (1994) Curr. Opin. Immunol. 6, 32-37 [Medline] [Order article via Infotrieve]
  3. Yang, Y., Früh, K., Chambers, J., Waters, J. B., Wu, L., Spies, T. & Peterson, P. A. (1992) J. Biol. Chem. 267, 11669-11672 [Abstract/Free Full Text]
  4. Woong-Kyung, S., Cohen-Doyle, M. F., Früh, K., Wang, K., Peterson, P. A. & Williams, D. B. (1994) Science 264, 1322-1326 [Medline] [Order article via Infotrieve]
  5. Michaelek, M. T., Grant, E. P., Gramm, C., Goldberg, A. L. & Rock, K. L. (1993) Nature 363, 552-554 [CrossRef][Medline] [Order article via Infotrieve]
  6. Hershko, A. & Ciechanover, A. (1992) Annu. Rev. Biochem. 61, 761-807 [CrossRef][Medline] [Order article via Infotrieve]
  7. Rock, K. L., Gramm, C., Rothstein, L., Clark, K., Stein, R., Dick, L., Hwang, D. & Goldberg, A. L. (1994) Cell 78, 761-771 [Medline] [Order article via Infotrieve]
  8. Hoffman, L. & Rechsteiner, M. (1994) J. Biol. Chem. 269, 16890-16895 [Abstract/Free Full Text]
  9. Peters, J. M., Franke, W. W. & Kleinschmidt, J. A. (1994) J. Biol. Chem. 269, 7709-7718 [Abstract/Free Full Text]
  10. Orlowski, M. (1990) Biochemstry 29, 10289-10297 [Medline] [Order article via Infotrieve]
  11. Rivett, A. J. (1993) Biochem. J. 291, 1-10 [Medline] [Order article via Infotrieve]
  12. Rechsteiner, M., Hoffman, L. & Dubiel, W. (1993) J. Biol. Chem. 268, 6065-6068 [Free Full Text]
  13. Lowe, J., Stock, D., Jap, B., Zwickl, P., Baumeister, W. & Huber, R. (1995) Science 268, 533-539 [Medline] [Order article via Infotrieve]
  14. Tanaka, K., Tamura, T., Yoshimura, T. & Ichihara, A. (1992) New Biol. 4, 173-187 [Medline] [Order article via Infotrieve]
  15. Akiyama, K., Yokota, K., Kagawa, S., Shimbara, N., Tamura, T., Akika, H., Nothwang, H. G., Noda, C., Tanaka, K. & Ichihara, A. (1994) Science 265, 1231-1234 [Medline] [Order article via Infotrieve]
  16. Peters, J. M., Cejka, Z., Harris, J. R., Kleinschmidt, J. A. & Baumeister, W. (1993) J. Mol. Biol. 234, 932-937 [CrossRef][Medline] [Order article via Infotrieve]
  17. Zwickl, P., Grziwa, A., Puhler, G., Dahlmann, B., Lottspeich, F. & Baumeister, W. (1992) Biochemistry 31, 964-972 [Medline] [Order article via Infotrieve]
  18. Tanahashi, N., Tsurumi, C., Tamura, T. & Tanaka, K. (1993) Enzyme & Protein 47, 241-251
  19. Martinez, C. K. & Monaco, J. J. (1991) Nature 353, 664-667 [CrossRef][Medline] [Order article via Infotrieve]
  20. Glynne, R., Powis, S. H., Beck, S., Kelly, A., Kerr, L. A. & Trowsdale, J. (1991) Nature 353, 357-360 [CrossRef][Medline] [Order article via Infotrieve]
  21. Kelly, A., Powis, S. H., Glynne, R., Radley, E., Beck, S. & Trowsdale, J. (1991) Nature 353, 667-668 [CrossRef][Medline] [Order article via Infotrieve]
  22. Früh, K., Yang, Y., Arnold, D., Chambers, J., Wu, L., Waters, J. B., Spies, T. & Peterson, P. A. (1992) J. Biol. Chem. 267, 22131-22140 [Abstract/Free Full Text]
  23. Yang, Y., Waters, J. B., Früh, K. & Peterson, P. A. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 4928-4932 [Abstract]
  24. Früh, K., Gossen, M., Wang, K., Bujard, H., Peterson, P. A. & Yang, Y. (1994) EMBO J. 13, 3236-3244 [Abstract]
  25. Arnold, D., Driscoll, J., Androlewicz, M., Hughes, E., Cresswell, P. & Spies, T. (1992) Nature 360, 171-174 [CrossRef][Medline] [Order article via Infotrieve]
  26. Momburg, F., Ortiz, N. V., Neefjes, J., Goulmy, E., van de Wal, Y., Spits, H., Powis, S. J., Butcher, G. W., Howard, J. C., Walden, P. & Hämmerling, G. (1992) Nature 360, 174-177 [CrossRef][Medline] [Order article via Infotrieve]
  27. Boes, B., Hengel, H., Ruppert, T., Multhaup, G., Koszinowski, U. H. & Kloetzel, P. M. (1994) J. Exp. Med. 179, 901-909 [Abstract]
  28. Driscoll, J., Brown, M. G., Finley, D. & Monaco, J. J. (1993) Nature 365, 262-264 [CrossRef][Medline] [Order article via Infotrieve]
  29. Gaczynska, M., Rock, K. L. & Goldberg, A. L. (1993) Nature 365, 264-267 [CrossRef][Medline] [Order article via Infotrieve]
  30. Aki, M., Shimbara, N., Takashina, M., Akiyama, K., Kagawa, S., Tamura, T., Tanahashi, N., Yoshimura, T., Tanaka, K. & Ichihara, A. (1994) J. Biochem. (Tokyo) 115, 257-269 [Abstract]
  31. Ustrell, V., Pratt, G. & Rechsteiner, M. (1995) Proc. Natl. Acad. U. S. A. 92, 584-588 [Abstract]
  32. DeMartino, G. N. & Slaufhter, C. A. (1993) Enzyme & Protein 47, 314-324
  33. Mott, J. D., Pramanik, B. C., Moomaw, C. R., Afendis, S. J., DeMartino, G. N. & Slaughter, C. A. (1994) J. Biol. Chem. 269, 31466-31471 [Abstract/Free Full Text]
  34. Realini, C., Dubiel, W., Pratt, G., Ferrell, K. & Rechsteiner, M. (1994) J. Biol. Chem. 269, 20727-20732 [Abstract/Free Full Text]
  35. Chu-Ping, M., Slaughter, C. A. & DeMartino, G. N. (1992) J. Biol. Chem. 267, 10515-10523 [Abstract/Free Full Text]
  36. Gossen, M. & Bujard, H. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 5547-5551 [Abstract]
  37. Frentzel, S., Pesold-Hurt, B., Seelig, A. & Kloetzel, P. M. (1994) J. Mol. Biol. 236, 975-981
  38. Patel, S. D., Monaco, J. J. & McDevitt, H. O. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 296-300 [Abstract]
  39. Gray, C. W., Slaughter, C. A. & DeMartino, G. N. (1994) J. Mol. Biol. 236, 7-15 [CrossRef][Medline] [Order article via Infotrieve]
  40. Tanaka, K., Fujiwara, T., Kumatori, A., Shin, S., Yoshimura, T., Ichihara, A., Tokunaga, F., Aruga, R., Iwanaga, S., Kakizuka, A. & Nakanishi, S. (1990) Biochemistry 29, 3777-3785 [Medline] [Order article via Infotrieve]
  41. Ludemann, R., Lerea, K. M. & Etlinger, J. D. (1993) J. Biol. Chem. 268, 17413-17417 [Abstract/Free Full Text]
  42. Etlinger, J. D., Li, S. X., Guo, G. G. & Li, N. (1993) Enzyme & Protein 47, 325-329
  43. Dubiel, W., Ferrel, K. & Rechsteiner, M. (1993) FEBS Lett. 323, 276-278 [CrossRef][Medline] [Order article via Infotrieve]
  44. Zwickl, P., Lottspeich, F. & Baumeister, W. (1992) FEBS Lett. 312, 157-160 [CrossRef][Medline] [Order article via Infotrieve]
  45. Wenzel, T., Eckerskorn, C., Lottspeich, F. & Baumeister, W. (1994) FEBS Lett. 349, 205-209 [CrossRef][Medline] [Order article via Infotrieve]
  46. Tector, M., Zhang, Q. & Salter, R. D. (1994) J. Biol. Chem. 269, 25816-25822 [Abstract/Free Full Text]

©1995 by The American Society for Biochemistry and Molecular Biology, Inc.